Remicade Market Report 2026

Remicade Market Overview

• The Remicade market growth in the historic period has been driven by increasing prevalence of autoimmune disorders, wider clinical acceptance of biologics • Market expansion is supported by increasing demand for biosimilar competition, rising investments in biologics manufacturing • Growth Driver: Impact Of Rising Autoimmune Disease Incidence On The Remicade Market • Market Trend: Advancements In Infliximab Formulations Boost Patient Adherence And Accessibility • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Remicade Market?

Remicade (infliximab) is a biologic medication classified as a tumor necrosis factor-alpha (TNF-α) inhibitor. It treats autoimmune conditions such as rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. By blocking TNF-α, a protein involved in inflammation, remicade helps reduce symptoms, prevent disease progression, and improve quality of life. The main types of disease indications for remicade are crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and plaque psoriasis. Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract, often leading to abdominal pain, severe diarrhea, weight loss, and fatigue. The routes of administration are subcutaneous, intravenous, and parenteral, and the end users are hospitals, clinics, ambulatory care, and home care.

What Is The Remicade Market Growth Forecast?

The remicade market size is expected to see strong growth in the next few years. It will grow to $3433.68 million in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing demand for biosimilar competition, rising investments in biologics manufacturing, expansion of home infusion care models, growing focus on personalized autoimmune therapies, advancements in monoclonal antibody development. Major trends in the forecast period include increasing use of tnf-alpha inhibitor therapies, rising adoption of biologic treatments for autoimmune diseases, growing preference for long-term disease control drugs, expansion of specialty infusion services, enhanced focus on patient-centered treatment outcomes.

Global Remicade Market Segmentation

1) By Disease Indication: Crohn’s disease, Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis, Ulcerative Colitis, Plaque psoriasis 2) By Route Of Administration: Subcutaneous, Intravenous, Parenteral 3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

What Is The Driver Of The Remicade Market?

The rising incidence of autoimmune diseases is expected to propel the growth of the remicade market going forward. Autoimmune diseases are conditions where the immune system mistakenly attacks the body's own healthy cells, tissues, or organs, perceiving them as foreign threats. The rising incidence of autoimmune diseases is attributed to a combination of genetic predisposition, environmental changes, increased exposure to pollutants, lifestyle factors, and improved diagnostic awareness. Remicade (infliximab) is used to manage autoimmune diseases by targeting and inhibiting tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine involved in conditions such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. For instance, in April 2025, according to GOV.UK, a UK-based government public health agency, in 2024, the prevalence of people aged 16 and over self-reporting a long-term musculoskeletal (MSK) condition was 17.9%, with females (20.0%) exhibiting a higher incidence compared to males (15.6%). Therefore, the rising incidence of autoimmune diseases drives the remicade industry.

Key Players In The Global Remicade Market

Major companies operating in the remicade market are Janssen Biotech Inc.

Global Remicade Market Trends and Insights

Major companies operating in the Remicade (infliximab) market are focusing on developing innovative solutions, such as subcutaneous formulations of biologic therapies, to meet the rising demand for greater patient convenience, improved treatment adherence, and more time-efficient alternatives to traditional intravenous dosing. Subcutaneous biologics allow patients to self-administer maintenance doses at home, reducing infusion-center visits and providing a more accessible option than conventional IV formulations. For instance, in March 2024, Celltrion USA, Inc., a US-based biopharmaceutical company, launched Zymfentra (infliximab-dyyb), the first FDA-approved subcutaneous formulation of infliximab. Zymfentra is indicated as maintenance therapy for adults with moderate-to-severe active ulcerative colitis (UC) and Crohn’s disease (CD), collectively known as inflammatory bowel disease (IBD). Approved for use following IV induction with an infliximab product, it offers a convenient, self-administered alternative for long-term disease management.

What Are Latest Mergers And Acquisitions In The Remicade Market?

In September 2024, Tharimmune Inc., a US-based biopharmaceutical company, acquired a global license from Intract Pharma for an undisclosed amount. This acquisition is aimed at developing an oral version of infliximab, which has traditionally been administered intravenously, thereby enhancing patient compliance and potentially reducing healthcare costs associated with long-term intravenous therapy. Intract Pharma Ltd. is a UK-based provider of infliximab.

Regional Insights

North America was the largest region in the remicade market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Remicade Market?

The remicade market consists of sales of biosimilars of remicade, combination therapy products, administration tools, and packaging formats. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Remicade Market Report 2026?

The remicade market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the remicade industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.